- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
Entrectinib, as a TRK/ROS1 inhibitor, should be used with a focus on neurological toxicity, cardiac risk, and special population management. Th...
Entrectinib, as a TRK/ROS1 inhibitor, commonly has side effects involving the nervous system, cardiovascular system, and digestive system, requ...
Upadacitinib, as a JAK1 inhibitor, should be used with a focus on infection risk, thrombotic events, laboratory indicator monitoring, and speci...
Upadacitinib, as a JAK inhibitor, commonly has side effects such as increased risk of infection and gastrointestinal reactions, which require t...
The contraindications of Crizotinib mainly involve specific drug interactions, severe underlying diseases, and special physiological states, ...
The medication precautions for Crizotinib involve multiple aspects such as liver function monitoring, cardiovascular risk management, and medic...
The usage and dosage of eltrombopag should be adjusted according to the indications, individual patient conditions, and dynamic platelet count....
As a thrombopoietin receptor agonist, eltrombopag requires strict adherence to dosage adjustment, monitoring, and special population management...
Doptelet, as a thrombopoietin receptor agonist, has contraindications mainly related to specific thrombotic risk populations and drug allergic ...
The usage and dosage of Dovtelet should be personalized according to the indications and patient types, mainly including preoperative platelet ...
